Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 studyAjay K. Nooka, Niels W.C.J. van de Donk, Cesar Rodriguez et al.|Cancer|2023Cited by 87
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A. Frerichs, Niels W.C.J. van de Donk, Clarissa Uhlar et al.|Blood Advances|2023Cited by 85
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Cesar Rodriguez, María‐Victoria Mateos et al.|Cancer|2023Cited by 66
Teclistamab: Mechanism of action, clinical, and translational scienceYue Guo, Danièle Ouellet, Natalia A. Quijano Cardé et al.|Clinical and Translational Science|2024Cited by 29
P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTSKristine A. Frerichs, Niels W.C.J. van de Donk, Christie P.M. Verkleij et al.|HemaSphere|2023Cited by 5